Correspondence: Nirmatrelvir–ritonavir suppresses viral load but may attenuate spike antibody response

Summary

This correspondence article discusses findings from the PANORAMIC trial published in The Lancet Microbe, showing that nirmatrelvir–ritonavir (Paxlovid) retains antiviral activity against omicron SARS-CoV-2 variants in a highly immune population. The treatment accelerated viral clearance, reduced culturable virus frequency, and showed no increased viral rebound, mutagenesis, or resistance. However, the authors highlight an important immunological observation: the treatment attenuated the infection-associated rise in spike antibody titres, which may have implications for immune memory and future protection against SARS-CoV-2.

Source

B

bskyCorrespondence: Nirmatrelvir–ritonavir suppresses viral load but may attenuate spike antibody responsethelancet.com